Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377371 · ClinicalTrials.gov registry record · Phase 4
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
A Phase 4 study of Meningioma, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06377371: Recruiting Phase 4 study of Meningioma, sponsored by Weill Medical College of Cornell University.
NCT06377371 is a Phase 4 study of Meningioma that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06377371, a Phase 4 study of Meningioma, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
Primary Outcome
preoperative lesion \[Cu64\]DOTATATE PET SUV
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Brain Imaging with [Cu64]DOTATATE
- PROCEDURE Radio-guided Surgery With Neoprobe Utilization
Study Locations (1)
New York
- New York-Presbyterian/Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
What NCT06377371 shows while recruiting
NCT06377371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Brain Imaging with [Cu64]DOTATATE is the first listed.
NCT06377371 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06377371 about?
NCT06377371 is a clinical study titled "Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE". The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
What is the current status of trial NCT06377371?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-09-11. Estimated completion is 2027-01.
What conditions does trial NCT06377371 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT06377371?
The interventions under investigation include: Brain Imaging with [Cu64]DOTATATE (DIAGNOSTIC_TEST), Radio-guided Surgery With Neoprobe Utilization (PROCEDURE).
Who is sponsoring clinical trial NCT06377371?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377371 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06377371's enrollment target sits among peer trials
20 19th of 21 higher than 2 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI